# US 2021/0260250 A1 · Methods for Enhanced Endothelialization of Implanted Material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260250 A1
- Document ID: US20210260250A1
- Status: Published application
- Kind: A1
- Application number: 16/973,809
- Filed: 2019-06-12
- Published: 2021-08-26
- Earliest claimed: 2018-06-12
- Assignees: Rush University Medical Center
- Applicants: Rush University Medical Center
- Inventors: Jeffrey Scott SOBLE; Uri GALILI; Gary SCHAER
- Web page: https://patentgrep.com/patent/US20210260250A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61F 2/0077: {Special surfaces of prostheses, e.g. for improving ingrowth (A61F2/30767 takes precedence)}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61F 2002/0086: {for preferentially controlling or promoting the growth of specific types of cells or tissues}
- A61L 2400/18: Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61L 2430/22: for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Methods and devices for increasing endothelialization on a surface of a medical device are provided. The methods include delivering the medical device to an intravascular site and the medical device has an α-gal epitope attached to the surface of the medical device.

## Claims

### Claim 1

A method of increasing endothelialization on a surface of a medical device, the method comprising delivering the medical device to an intravascular site, the medical device having an α-gal epitope attached to the surface of the medical device.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the α-gal epitope is attached to the surface comprising an intraluminal surface of the medical device.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the intravascular site is within an artery or a vein.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the intravascular site is a cardiac site.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the medical device comprises a synthetic or biological device.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the medical device is selected from the group consisting of a valve, a stent, an occlusion device, a graft or a synthetic blood vessel.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the medical device comprises polyethylene terephthalate (PET) or polytetrafluoroethylene (PTFE) or expanded polytetrafluoroethylene (ePTFE).

### Claim 8

An implant device comprising a medical device comprising an α-gal epitope attached to a surface of the medical device.

### Claim 9 (depends on 8)

The implant device according to claim 8, wherein the α-gal epitope is attached to a luminal surface of the medical device.

### Claim 10

A method of making an implant device, the method comprising:
attaching an α-gal epitope to a surface of a medical device.

### Claim 11 (depends on 10)

The method according to claim 10, comprising attaching the α-gal epitope to a luminal surface of the medical device.

### Claim 12 (depends on 10)

The method according to claim 10, comprising attaching the α-gal epitope by crosslinking the α-gal epitope to the surface of the medical device.

### Claim 13 (depends on 10)

The method according to claim 10, wherein the α-gal epitope is linked to albumin and the albumin linked α-gal epitope is attached to the surface of the medical device by crosslinking.

### Claim 14 (depends on 10)

The method according to claim 10, comprising attaching the α-gal epitope by denaturing the α-gal epitope onto the surface of the medical device with heat.

### Claim 15 (depends on 10)

The method according to claim 10, wherein the α-gal epitope is linked to albumin and the albumin linked α-gal epitope is attached to the surface of the medical device by denaturing with heat.

### Claim 16 (depends on 10)

The method according to claim 10, wherein the α-gal epitope is attached to the surface of the medical device with a linker.

### Claim 17 (depends on 10)

The method according to claim 10, wherein the α-gal epitope is purified from a mammalian glycoprotein source.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the α-gal epitope is purified from mouse laminin or bovine thyroglobulin.
